Nektar Therapeutics Presents Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer
Nektar Therapeutics (NASDAQ: NKTR) announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California. NKTR-102 is a novel topoisomerase I inhibitor designed using Nektar's proprietary polymer conjugate technology, and is being developed in multiple tumor settings.
"NKTR-102 exhibits a very high response rate and excellent clinical benefit rate in patients with metastatic breast cancer, and importantly, this anti-tumor activity is maintained in each of the poor prognosis subsets within the study," said presenter and NKTR-102 study investigator, Dr. Agustin Garcia, Associate Professor of Clinical Medicine at USC Norris Comprehensive Center. "The data from the Phase 2 study also shows highly promising PFS of 5.3 months and OS of 13.1 months in the every three week dose schedule, which was also very well-tolerated. As a novel topoisomerase I inhibitor in breast cancer, NKTR-102 holds great therapeutic potential and allows us to address the challenge of resistance in this setting. The investigators look forward to the initiation of the Phase 3 BEACON study of NKTR-102 in patients with metastatic breast cancer."
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.